Proteoglycans and WTI as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium

Journal of Pathology

Volumn 199, Issue 4, 2003, Pages 479-487

  Gulyás, Miklós ^a   Hjerpe, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenocarcinoma; Hyaluronan; Mesothelioma; Mesothelium; Proteoglycans; WT1

Indexed keywords

BIGLYCAN; EPITOPE; HYALURONIC ACID; MESSENGER RNA; PROTEOGLYCAN; SYNDECAN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 4; SYNTHETASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VERSICAN; CSPG2 PROTEIN, HUMAN; LECTIN; MEMBRANE PROTEIN; PROTEOCHONDROITIN SULFATE; SCLEROPROTEIN; SDC1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; WT1 PROTEIN;

ADENOCARCINOMA; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EFFUSION; EPITHELIUM; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; MESENCHYME; MESOTHELIOMA; MESOTHELIUM CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DIFFERENTIATION; CELL CULTURE; EPITHELIUM CELL; METABOLISM;

ADENOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LECTINS, C-TYPE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; NEOPLASM PROTEINS; PROTEOCHONDROITIN SULFATES; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNDECAN-1; SYNDECANS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VERSICANS; WT1 PROTEINS;

EID: 0037385305     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1312     Document Type: Article

References (35)

1. Nurminen M, Dejmek A, Mårtenson G, Thylen A, Hjerpe A. Clinical utility of liquid chromatographic analysis of effusions for hyaluronate content. Clin Chem 1994; 40: 777-780.
2. Brockstedt U, Gulyás M, Dobra K, Dejmek A, Hjerpe A. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000; 114: 203-209.
3. Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol 2001; 116: 253-262.
4. Landolt RM, Vaughan L, Winterhalter KH, Zimmermann DR. Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth. Development 1995; 121: 2303-2312.
5. Lories V, Cassiman JJ, Van den Berghe H, David G. Differential expression of cell surface heparan sulfate proteoglycans in human mammary epithelial cells and lung fibroblasts. J Biol Chem 1992; 267: 1116-1122.
6. Inki P, Larjava H, Haapasalmi K, Miettinen HM, Grenman R, Jalkanen M. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Eur J Cell Biol 1994; 63: 43-51.
7. David G, Bai XM, Van der Schueren B, Marynen P, Cassiman JJ, Van den Berghe H. Spatial and temporal changes in the expression of fibroglycan (syndecan-2) during mouse embryonic development. Development 1993; 119: 841-854.
8. Woods A, Couchman JR. Syndecan-4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. J Cell Sci 1992; 313: 87-96.
9. Cook DM, Hinkes MT, Bernfield M, Rauscher III FJ. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 1996; 13: 1789-1799.
10. Huang A, Campbell CE, Bonetta L, et al. Tissue, developmental and tumor-specific expression of divergent transcripts in Wilms' tumor. Science 1990; 250: 991-994.
11. Park S, Schalling M, Bernard A, et al. The Wilms' tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in human mesothelioma. Nature Genet 1993; 4: 415-420.
12. Gulyás M, Dobra K, Hjerpe A. Expression of genes coding for proteoglycans and Wilms' tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cells. Differentiation 1999; 65: 89-96.
13. Klominek J, Robért KH, Bergh J, Hjerpe A, Gahrton G, Sundqvist KG. Production of a motility factor by a newly established lung adenocarcinoma cell line. Anticancer Res 1998; 18: 759-768.
14. Klominek J, Robert KH, Hjerpe A, Wickström B, Gahrton G. Serum-dependent growth patterns of two, newly established human mesothelioma cell lines. Cancer Res 1989; 49: 6118-6122.
15. Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, et al. Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis 1990; 11: 673-681.
16. Dobra K, Andäng M, Syrokou A, Karamanos NK, Hjerpe A. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp Cell Res 2000; 258: 12-22.
17. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995; 146: 344-356.
18. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194-204.
19. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition and prognosis. J Pathol 1997; 181: 67-74.
20. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1 and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000; 24: 598-606.
21. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36: 341-347.
22. Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001; 125: 1316-1320.
23. Inki P, Joensuu H, Grenman R, Klemi P, Jalkanen M. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 1994; 70: 319-323.
24. Kumar-Singh S, Jacobs W, Dhaene K, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression and clinical outcome. J Pathol 1998; 186: 300-305.
25. Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998; 185: 290-297.
26. Yung S, Woods A, Chan TM, Davies M, Williams JD, Couchman JR. Syndecan-4 up-regulation in proliferative renal disease is related to microfilament organization. FASEB J 2001; 15: 1631-1633.
27. Echtermeyer F, Streit M, Wilcox-Adelman S, et al. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001; 107: R9-R14.
28. Shimazu A, Bachchu MA, Morishita M, Noshiro M, Kato Y, Iwamoto Y. Expression of syndecan-2, -4 and fibroblast growth factor receptor type 1 in human periodontal ligament fibroblasts and down-regulation of these membrane proteins during maturation in culture. J Dental Res 1999; 78: 1791-1799.
29. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 1990; 38: 1549-1563.
30. Schaefer L, Hausser H, Altenburger M, et al. Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int 1998; 54: 1529-1541.
31. Isogai Z, Shinomura T, Yamakawa N, et al. 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res 1996; 56: 3902-3908.
32. Nara Y, Kato Y, Torii Y, et al. Immunohistochemical localization of extracellular matrix components in human breast tumors with special reference to PG-M/versican. Histochem J 1997; 29: 21-30.
33. Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, Lebaron RG, Horsfall DJ. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta 1. Cancer Res 2001; 61: 926-930.
34. Zimmermann DR, Dours-Zimmermann MT, Schubert M, Bruckner-Tuderman L. Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 1994; 124: 817-825.
35. Gulyás M, Kaposi AD, Elek G, Szollár LG, Hjerpe A. Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol 2001; 54: 831-835.